White Blood Count, Albumin, and BMI Enhance VACS Index Prognostic Model, but Nadir CD4 and CD8 Metrics Do Not

Janet P. Tate, VA Connecticut Healthcare System
Sheldon Brown, Mt Sinai School of Medicine
Cynthia Gibert, VAMC
Matthew Goetz, VA Greater Los Angeles Healthcare System
Vincent Marconi, Emory University
Kris Ann Oursler, Salem VA Medical Center
David Rimland, Emory University
Maria Rodriguez-Barradas, Michael E. DeBakey VA Medical Center
Amy C. Justice, Yale University

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: Oxford University Press (OUP) | 2017-10-04, Pages S210-S210
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1093/ofid/ofx163.415
Permanent URL: https://pid.emory.edu/ark:/25593/s6fc2

Final published version: http://dx.doi.org/10.1093/ofid/ofx163.415

Copyright information:
© The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed November 11, 2019 11:42 AM EST
560. The Impact of Continuous Virologic Suppression on the Development of Non-AIDS Diagnoses

Christie Joya, DO; Seunghyun Won, PhD; Robert Deiss, MD; Jason Okulicz, MD; Thomas O’Bryan, MD; Ryan Maves, MD, FACP, FIDSA; Christina Schofield, MD, FACP, FIDSA; Thomas Ferguson, MD, FIDSA; Timothy J. Whitman, DO; Brenda Elgan, MD and Amrutha Velayudhan, MD.

Reed National Military Medical Center, Bethesda, Maryland; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, Infectious Disease, San Antonio National Fort Sam Houston, Texas; Division of Infectious Diseases, Naval Medical Center San Diego, San Diego, California; Madigan Army Medical Center, Tacoma, Washington; Department of Medicine, Tripler Army Medical Center, Honolulu, Hawaii; Walter Reed National Military Medical Center, Bethesda, Maryland; Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences, Rockville, Maryland; Department of Preventive Medicine and Biostatistics, Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Rockville, Maryland.

Session: 63. HIV Clinical Care and Outcomes
Thursday, October 5, 2017: 12:30 PM

Background. In the era of effective antiretroviral therapy (ART) non-AIDS diagnoses (NAD) have emerged as significant concerns. HIV viremia is an important driver of systemic inflammation that has been linked to the development of NAD. In this study, we examined the distribution of NAD in a group of early diagnosed and treated HIV-infected individuals with equal access to care to evaluate the effect of continuous virologic suppression (CS) on NAD.

Methods. The U.S. Military HIV Natural History Study (NHS) is a prospective cohort of HIV-infected DoD beneficiaries the majority of whom are deroconverters. Medical record review and structured interviews are utilized to capture NAD. We included subjects initiating ART after 1996 if they had ≥2 viral loads (VLs) measured while on ART. CS was defined as having all VLs <50 copies/mL. A Cox proportional hazard model was used to evaluate the association between CS and NAD.

Results. Of the 2,642 eligible participants (93% male, 43% African-American AA), median follow-up 6.5 (IQR 3.3–12) years, 945 (37.3%) subjects (94% male, 42% AA, median follow-up 3.74 years) met criteria for CS. The median time from HIV diagnosis to ART initiation was 1.34 (IQR 0.19–5.46) years, while the median seroconversion window was 1.31 (IQR 0.8–2.1) years. A total of 402 (15.2%) NAD were recorded and were recorded (table). Factors associated with NAD included older age at ART initiation (HR 1.6 per 10-year increase [95% CI 1.4–1.8]) and female gender (HR 1.6 [95% CI 1.0–2.7]), while a higher CD4 count was protective (HR 0.93 per 50 CD4 cell increase [95% CI 0.90–0.95]). CS status was not associated with NAD (HR 0.75 [95% CI 0.50–1.11]).

Conclusion. In the ART era, about 1 in 7 NHS subjects had a NAD. The numbers of NAD in the CS subjects were lower than the rest of the cohort. While not statistically significant, the hazard ratios trended towards demonstrating a benefit for continuous virologic suppression. This trend is consistent with previous reports that have demonstrated a benefit of immunologic reconstitution and virologic control on the incidence of NAD.

Disclosures. All authors: No reported disclosures.

561. Screening for Comorbid Conditions Among People with HIV in Medical Care

Rachael Lazar, MPH1; Laura Kersanske, MPH1 and Sarah Braunstein, PhD, MPH2.


Session: 63. HIV Clinical Care and Outcomes
Thursday, October 5, 2017: 12:30 PM

Background. A significant proportion of morbidity and mortality among people living with HIV (PLWH) is attributable to non-HIV comorbid conditions. Despite the importance of detecting and treating comorbidities among PLWH, screening rates for common comorbidities are often suboptimal and may not correspond with risk factor status.

Methods. Comorbidities screening and other clinical data were obtained from the 2012 New York City (NYC) Medical Monitoring Project (MMP), a multi-site surveillance project comprised of demographically representative cohorts of PLWH receiving medical care. MMP medical record abstraction data were analyzed to